Currently there is no approved treatment for NPHP5 retinal degeneration. Companies are focusing on developing gene and cell therapies to treat the underlying genetic cause of the disease. Promising treatment modalities currently under research include AAV gene therapy, RNA therapies, stem cell transplantations and genome editing tools like CRISPR.
The Global NPHP5 Retinal Degeneration Treatment Market is estimated to be valued at US$ 15.7 Mn in 2024 and is expected to exhibit a CAGR of 35.4% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the global NPHP5 retinal degeneration treatment market are ProQR Therapeutics, Editas Medicine, Nanoscope Therapeutics, Inc., jCyte, Inc., Biogen, Novartis AG, Spark Therapeutics, MeiraGTx, NightstaRx, Beacon Therapeutics, Applied Genetic Technologies Corporation, ViGeneron and RetinAI Medical. Growing research in genetic technologies and personalized medicine is driving the demand for specialized treatments for rare retinal genetic diseases like NPHP5 retinal degeneration. Major companies are focusing their clinical trial efforts in developed markets of North America and Europe to advance their retinal disease treatment candidates.
Market drivers
The rising investment from venture capital firms, philanthropic foundations and life science companies in developing gene and cell therapies for inherited retinal diseases is a major growth driver for the Global NPHP5 Retinal Degeneration Treatment Market . Significant research funding from organizations like Foundation Fighting Blindness, American Macular Degeneration Foundation along with support from government bodies is encouraging pharmaceutical companies and startups to focus on retinal disease treatment development. This is expected to accelerate the drug development pipelines and clinical research efforts in this market over the forecast period.
Impact of Geopolitical Situation on Market Growth
The growth of the global NPHP5 retinal degeneration treatment market has been impacted by geopolitical issues in recent years. Since several key players involved in retinal degeneration research and development are based in the United States and Europe, trade tensions and sanctions have disrupted collaborations and international clinical trials. The conflict between Russia and Ukraine has also stalled ongoing trials in Eastern European countries. However, rising investment in ophthalmology research from China and India is helping offset some of the losses. Looking ahead, for sustainable growth, companies will need to diversify their global partnerships, consider virtual and decentralized clinical trial models, and focus on developing diversified manufacturing and supply chains that are less vulnerable to trade disruptions.
Get more insights on - Global NPHP5 Retinal Degeneration Treatment Market
